Physician profile
Keith A Gray
NPI 1033195177
$7,952.71
in general payments reported to CMS, 2019-2025
34 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,292 · 2020: $1,122 · 2021: $1,156 · 2022: $761 · 2023: $1,359 · 2024: $813 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,548 · Gift: $59.40 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.61 |
| Gift | $59.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,560.04 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,094.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $754.09 | 2019-2025 | |
| Amgen INC. | $727.99 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $514.22 | 2022-2025 | |
| Lilly USA, LLC | $444.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $330.19 | 2019-2023 | Seglentis, Livalo |
| Pfizer INC. | $266.34 | 2019-2024 | |
| Mannkind Corporation | $266.08 | 2022-2023 | Afrezza |
| Glaxosmithkline, LLC. | $249.47 | 2019-2025 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $241.23 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.57 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $183.97 | 2019-2025 | Capvaxive |
| Sanofi-Aventis U.S. LLC | $147.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $128.40 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.86 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $107.64 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $106.07 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $72.66 | 2023-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $56.72 | 2020-2021 | |
| Gilead Sciences, INC. | $46.30 | 2019-2020 | |
| Renalytix Ai, INC. | $42.86 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Phathom Pharmaceuticals, INC. | $29.59 | 2024 | Voquezna |
| Medicure Pharma INC. | $29.29 | 2022-2024 | Zypitamag |
| Alnylam Pharmaceuticals INC. | $29.12 | 2023 | Onpattro |
| Averitas Pharma INC. | $24.24 | 2024 | Qutenza |
| Allergan, INC. | $23.81 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $23.72 | 2019 | |
| Abiomed | $21.85 | 2025 | |
| Medtronic, INC. | $21.76 | 2025 | Inceptiv |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.28 | 2022 | |
| Abbott Laboratories | $16.96 | 2022 | |
| Corcept Therapeutics | $14.37 | 2025 | Korlym |
| Arbor Pharmaceuticals, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.